SCHEMBL9281981

SCHEMBL9281981

CCc1cc(NCc2cc(C)c(C)nc2OC)c(=O)[nH]c1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.37
KDM4E B2RXH2 7/20 0.37
GAA P10253 6/20 0.36
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
IDH1 O75874 3/20 0.33
APAF1 O14727 2/20 0.33
LMNA P02545 1/20 0.33
RECQL P46063 1/20 0.33
PDE1A P54750 1/20 0.31
PDE1B Q01064 1/20 0.31
PDE1C Q14123 1/20 0.31
ALDH1A1 P00352 2/20 0.31
NPC1 O15118 1/20 0.31
ALOX15 P16050 1/20 0.31
MAPK1 P28482 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9333881 0.92 MAPT (0.35) MAPTKDM4EGAAPDE3BPDE3A
SCHEMBL9846154 0.90 MAPT (0.38) MAPTKDM4EGAAIDH1APAF1
SCHEMBL17162118 0.87 MAPT (0.32) MAPTKDM4EGAA
SCHEMBL9681421 0.86 MAPT (0.37) MAPTKDM4EGAAIDH1APAF1
SCHEMBL9246249 0.85 MAPT (0.32) MAPTKDM4EGAAPDE3BPDE3A
SCHEMBL9246243 0.85 PDE1A (0.32) MAPTKDM4EGAAPDE3BPDE3A
SCHEMBL9846298 0.82 PDE3B (0.38) MAPTKDM4EGAAPDE3BPDE3A
SCHEMBL9846230 0.82 BTK (0.41) MAPTKDM4EGAAIDH1APAF1
SCHEMBL9846089 0.80 NPSR1 (0.38) MAPTKDM4EGAAPDE3BPDE3A
SCHEMBL9168694 0.80 PDE3B (0.42) MAPTKDM4EGAAPDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0484071-A2 Synergism of HIV reverse transcriptase inhibitors MERCK & CO. INC. (US) 1992-05-06 EP claimed
EP-0462800-A2 Inhibitors of HIV reverse transcriptase MERCK & CO. INC. (US) 1991-12-27 EP claimed
EP-0666744-A1 USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION THE UPJOHN COMPANY (US) 1995-08-16 EP disclosed
WO-1994009781-A1 USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION THE UPJOHN COMPANY (US) 1994-05-11 WO disclosed
EP-0484071-A2 Synergism of HIV reverse transcriptase inhibitors MERCK & CO. INC. (US) 1992-05-06 EP disclosed
EP-0462800-A2 Inhibitors of HIV reverse transcriptase MERCK & CO. INC. (US) 1991-12-27 EP disclosed